Masaharu Higashida Selected Research

S-1 plus cisplatin

12/2019

[HER2-Positive Advanced Gastric Cancer with Para-Aortic Lymph Node Metastases Treated with Conversion Surgery after Chemotherapy-A Case Report].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masaharu Higashida Research Topics

Disease

15	Neoplasms (Cancer) 12/2023 - 10/2013
14	Stomach Neoplasms (Stomach Cancer) 12/2023 - 06/2007
10	Esophageal Neoplasms (Esophageal Cancer) 01/2023 - 12/2006
8	Neoplasm Metastasis (Metastasis) 12/2023 - 11/2008
4	Colorectal Neoplasms (Colorectal Cancer) 10/2023 - 11/2015
3	Carcinoma (Carcinomatosis) 01/2023 - 05/2012
3	Lymphatic Metastasis 12/2021 - 12/2019
2	Lung Neoplasms (Lung Cancer) 10/2023 - 10/2020
2	Neuroendocrine Carcinoma 12/2021 - 04/2020
2	Acute Cholecystitis 03/2021 - 03/2016
1	Adenocarcinoma of Lung 10/2023
1	Pulmonary Atelectasis 10/2023
1	Esophageal Stenosis (Esophageal Stricture) 10/2023
1	Pneumonia (Pneumonitis) 05/2023
1	Malnutrition (Nutritional Deficiencies) 04/2023
1	Sigmoid Neoplasms 04/2023
1	Heart Failure 04/2023
1	Hypoalbuminemia 01/2023
1	Inflammation (Inflammations) 01/2023
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2022
1	Residual Neoplasm 01/2022
1	Postoperative Hemorrhage 04/2021
1	Lung Diseases (Lung Disease) 10/2020
1	Margins of Excision 10/2020
1	Anorexia 03/2020
1	Rectal Neoplasms (Rectal Cancer) 01/2020
1	Esophageal Squamous Cell Carcinoma 06/2019
1	Acalculous Cholecystitis 03/2016
1	Cholecystitis 03/2016
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2014
1	Leukopenia 05/2012
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 11/2008
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 12/2006
1	Purpura 08/2006

Drug/Important Bio-Agent (IBA)

6	Docetaxel (Taxotere)FDA Link 01/2017 - 12/2006
5	Fluorouracil (Carac)FDA LinkGeneric 01/2017 - 12/2006
3	Carboplatin (JM8)FDA LinkGeneric 10/2023 - 04/2020
3	titanium silicide (TS-1)IBA 01/2017 - 11/2012
2	NivolumabIBA 12/2023 - 10/2020
2	C-Reactive ProteinIBA 01/2023 - 04/2021
2	Eicosapentaenoic AcidIBA 01/2017 - 10/2013
2	nedaplatinIBA 05/2012 - 05/2007
1	pembrolizumabIBA 10/2023
1	Immune Checkpoint InhibitorsIBA 10/2023
1	MetalsIBA 08/2023
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2023
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	AlbuminsIBA 01/2023
1	AntigensIBA 12/2022
1	Gemcitabine FDA Link 12/2022
1	CarbohydratesIBA 12/2022
1	130-nm albumin-bound paclitaxelIBA 12/2022
1	vasectrin I (VS I)IBA 01/2022
1	4-azidosalicylic acid-phosphatidylserineIBA 01/2022
1	Etoposide (VP 16)FDA LinkGeneric 12/2021
1	Immunologic Factors (Immunomodulators)IBA 04/2021
1	S-1 plus cisplatinIBA 12/2019
1	Trastuzumab (Herceptin)FDA Link 12/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2017
1	Carnitine (L-Carnitine)FDA LinkGeneric 01/2017
1	Cisplatin (Platino)FDA LinkGeneric 01/2017
1	TegafurIBA 07/2014
1	PotassiumIBA 07/2014
1	NF-kappa B (NF-kB)IBA 10/2013
1	Interleukin-6 (Interleukin 6)IBA 10/2013
1	CytokinesIBA 10/2013
1	Imatinib Mesylate (Gleevec)FDA Link 11/2008
1	Factor XIII (Coagulation Factor XIII)IBA 08/2006

Therapy/Procedure

13	Drug Therapy (Chemotherapy) 12/2023 - 05/2007
10	Gastrectomy 12/2023 - 03/2017
9	Therapeutics 10/2023 - 12/2006
4	Lymph Node Excision (Lymph Node Dissection) 12/2023 - 03/2020
3	Chemoradiotherapy 06/2019 - 05/2007
2	Esophagectomy 04/2021 - 08/2017
2	Laparoscopic Cholecystectomy 03/2021 - 03/2016
2	Neoadjuvant Therapy 01/2020 - 06/2019
2	Adjuvant Chemotherapy 11/2012 - 06/2007
2	Radiotherapy 05/2012 - 11/2009
2	Combination Drug Therapy (Combination Chemotherapy) 05/2012 - 05/2007
1	Colostomy 04/2023
1	Cholecystectomy 03/2020
1	Self Expandable Metallic Stents 01/2019
1	Decompression 01/2019
1	Stents 01/2019
1	Induction Chemotherapy 12/2018
1	Perioperative Period 08/2017
1	Oral Administration 06/2007